Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115765
Status:
COMPLETED
Last Update Posted:
2018-10-17
First Post:
2005-06-26
Brief Title:
PACCE Panitumumab Advanced Colorectal Cancer Evaluation Study
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
PACCE A Randomized Open-Label Controlled Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess whether treatment with the study drug panitumumab given concomitantly with every 2 Q2 week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival PFS compared to treatment Q2-week with oxaliplatin-based chemotherapy and bevacizumab alone All subjects will receive Q2-week oxaliplatin- or irinotecan-based chemotherapy and bevacizumab Control arm subjects will not receive concomitant panitumumab therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None